

Study: ARX-945-RA-II

Protocol: CT-204-II

Sponsor: Ardentis Biotherapeutics Ltd.

Site No.: 104

Subject ID: 1

Document: Adverse Events

AE ID	Onset Date	End Date	AE Term (Verbatim)	Severity (Grade)	Serious (Y/N)	Relation to Study Drug	Action Taken	Outcome
AE-001	2025-11-18	2025-11-19	Headache, Mild	1	N	Possible	None	Resolved
AE-002	2025-12-28	2025-12-30	Upper Respiratory Infection	2	N	Unlikely	None	Resolved
AE-003	2026-01-05	Ongoing	Fatigue	1	N	Possible	None	Ongoing